Europe
Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look.
Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth.
Psychedelic-focused drug company Eleusis is merging with Silver Spike Acquisition Corp. II, a special purposes acquisition company, and heading to the Nasdaq with a combined enterprise value of $446 million.
World tennis superstar Novak Djokovic reportedly has an 80% stake in QuantBioRes that’s currently working on finding a treatment, not a vaccine, for COVID-19.
Dr. Anthony Fauci expects the FDA will authorize the Pfizer-BioNTech vaccine for children under the age of five in the next month.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The company plans to use the money to boost its drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.
The companies announced that Dupixent was the first biologic to significantly reduce itch and skin lesions in patients with Prurigo Nodularis in the Phase III trial.
A study conducted by 23andMe and published in Nature Genetics identified a genetic risk factor tied to the loss of smell from COVID-19.
UCB has announced that it is acquiring Zogenix as part of plans to expand its reach into commercializing and developing treatments for rare diseases.
PRESS RELEASES